Your session is about to expire
← Back to Search
Personalized Dietary Management for Type 2 Diabetes (DiaTeleMed Trial)
N/A
Recruiting
Led By Mary Sevick, ScD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must be an adult 21-80 years of age
Be older than 18 years old
Must not have
Those who have been diagnosed with a chronic active inflammatory or neoplastic disease in the past 3 years
Those who have been prescribed: (1) antibiotics or antifungals in the past 3 months, (2) diabetic medications other than metformin, (3) weight loss medications, (4) chronic use of steroids or immunosuppressants, (5) atypical antipsychotics, and (6) chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 3
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether a Standardized or Personalized treatment plan is better for early-stage T2D than the Usual Care Control.
Who is the study for?
Adults aged 21-80 with early-stage Type 2 Diabetes (T2D), HbA1c<8%, on a stable diabetes regimen including metformin, able to use a smartphone and attend online sessions. Excludes those with certain chronic diseases, unable or unwilling to follow the diet plan, pregnant women, those with limited mobility or control over their diet, substance abusers, and people on specific medications.
What is being tested?
The trial is testing how effective personalized dietary guidance is at managing blood sugar after meals compared to standardized advice and usual care in people with T2D. It randomly assigns participants into three groups: Standardized Guidance Group, Personalized Guidance Group, or Usual Care Control Group.
What are the potential side effects?
Since this trial focuses on dietary management rather than medication or invasive procedures, side effects are minimal but may include potential discomfort from changing eating habits such as digestive changes or food cravings.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 21 and 80 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with a long-term inflammatory or cancerous disease in the last 3 years.
Select...
I have not taken antibiotics, antifungals, certain diabetes drugs, weight loss drugs, steroids, immunosuppressants, atypical antipsychotics, or chemotherapy in the last 3 months.
Select...
I need a special diet due to kidney disease, cirrhosis, or HIV.
Select...
I am unable or unwilling to give my consent for participation.
Select...
I have a long-term gut condition like Crohn's disease or celiac.
Select...
I need a walker or cane to walk 2 city blocks.
Select...
I am willing to accept any treatment group I am assigned to.
Select...
I have a chronic condition like Cushing's, acromegaly, or hyperthyroidism.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ month 3
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 3
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean Amplitude of Glycemic Excursion (MAGE)
Secondary study objectives
HbA1c Levels
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Usual Care Control (UCC)Experimental Treatment1 Intervention
Baseline advice about the Mediterranean-style diet and attention control.
Group II: PersonalizedActive Control3 Interventions
Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
Group III: StandardizedActive Control2 Interventions
One-size-fits-all dietary counseling to follow a Mediterranean-style diet
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,410 Previous Clinical Trials
855,351 Total Patients Enrolled
National Institute of Nursing Research (NINR)NIH
600 Previous Clinical Trials
10,377,324 Total Patients Enrolled
Mary Sevick, ScDPrincipal InvestigatorNYU Langone Health
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have early-stage Type 2 Diabetes with HbA1c under 8%, managed with lifestyle changes and metformin for the past 3 months.You have limited control over what you eat, for example, if you are homeless, in a nursing home, or in jail.I have been diagnosed with a long-term inflammatory or cancerous disease in the last 3 years.I have not taken antibiotics, antifungals, certain diabetes drugs, weight loss drugs, steroids, immunosuppressants, atypical antipsychotics, or chemotherapy in the last 3 months.My health condition or treatment does not significantly affect my body's microbiome, insulin response, or ability to lose weight.I need a special diet due to kidney disease, cirrhosis, or HIV.I am unable or unwilling to give my consent for participation.You currently have a problem with using drugs or alcohol.I have had bariatric surgery or am not willing to wait 7 months for it.I have a long-term gut condition like Crohn's disease or celiac.I need a walker or cane to walk 2 city blocks.I am willing to accept any treatment group I am assigned to.I am between 21 and 80 years old.I have a chronic condition like Cushing's, acromegaly, or hyperthyroidism.I can use English software for self-monitoring without issues.
Research Study Groups:
This trial has the following groups:- Group 1: Personalized
- Group 2: Usual Care Control (UCC)
- Group 3: Standardized
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger